Drug
Larazotide acetate clinical trials
Also written INN-202 and AT-1001.
A product of Larazotide; its studies count on that page too.
- studies test it
- 12
- open now
- 0
- in phase 3
- 0
- first study started
- 2005
How studies write it
Studies that test it under each name
Name
Combined with it in one product
Studies by the year they started
12 studies that test it; most in 2011 (4)
| Year | Studies |
|---|---|
| 2005 | 1 |
| 2006 | 2 |
| 2007 | 1 |
| 2008 | 1 |
| 2009 | 1 |
| 2011 | 4 |
| 2021 | 1 |
| 2023 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 5
- Phase 2
- 7
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 10 · Other 2
9 Meters Biopharma, Inc. (7) · Amicus Therapeutics (3) · Massachusetts General Hospital (2)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses larazotide acetate is read from its arms, and is right about nine times in ten.
Testing it · 12
- AT1001 for the Treatment of Long COVIDCompletedPhase 2Massachusetts General HospitalNCT05747534Written as Larazotide Acetate
- AT1001 for the Treatment of COVID-19 Related MIS-CTerminatedPhase 2Massachusetts General HospitalNCT05022303Written as Larazotide Acetate
- Study of the Efficacy of Larazotide Acetate to Treat Celiac DiseaseCompletedPhase 29 Meters Biopharma, Inc.NCT00889473Written as Larazotide acetate
- Study to Assess the Efficacy of Larazotide Acetate for the Treatment of Celiac DiseaseCompletedPhase 29 Meters Biopharma, Inc.NCT00492960Written as larazotide acetate
- A Double-blind Placebo-controlled Study to Evaluate Larazotide Acetate for the Treatment of Celiac DiseaseCompletedPhase 29 Meters Biopharma, Inc.NCT01396213Written as Larazotide Acetate
- Randomized, Double-Blind, Placebo-Controlled Study of Larazotide Acetate in Subjects With Active Celiac DiseaseCompletedPhase 29 Meters Biopharma, Inc.NCT00620451Written as larazotide acetate
- Safety of Larazotide Acetate in Healthy VolunteersCompletedPhase 19 Meters Biopharma, Inc.NCT00386490Written as larazotide acetate
- Safety and Tolerability Study of Larazotide Acetate in Celiac Disease SubjectsCompletedPhase 29 Meters Biopharma, Inc.NCT00362856Written as larazotide acetate
- Safety Study of Larazotide Acetate to Treat Celiac Disease.CompletedPhase 19 Meters Biopharma, Inc.NCT00386165Written as larazotide acetate
- Safety and Pharmacokinetics of AT1001 (Migalastat HCl) in Healthy Subjects and Subjects With Impaired Renal FunctionCompletedPhase 1Amicus TherapeuticsNCT01730469Written as AT1001 150 mg
- A Study to Assess the Absorption, Metabolism and Excretion of Migalastat Hydrochloride (AT1001-014)CompletedPhase 1Amicus TherapeuticsNCT01730482Written as [14C] AT1001
- A Phase I, Randomized, Single-Blind, Four-Period Cross-Over, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety and Pharmacokinetics of Single Oral Doses of GR181413A/AT1001 in Healthy Japanese SubjectsCompletedPhase 1Amicus TherapeuticsNCT01853852Written as GR181413A/AT1001 solution
Codes
What other systems call larazotide acetate · ClinicalTrials.gg INT005200
- MeSH (NLM) C525167larazotide acetateOne source NLM
- UNII (FDA) FO8S2IW40NLARAZOTIDE ACETATEConfirmed FDA, NLM
- NCI Thesaurus C81670Larazotide AcetateOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C525167 | larazotide acetate | One source NLM |
| UNII (FDA) | FO8S2IW40N | LARAZOTIDE ACETATE | Confirmed FDA, NLM |
| NCI Thesaurus | C81670 | Larazotide Acetate | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.